NASDAQ:LPCN Lipocine (LPCN) Stock Price, News & Analysis → Bible Shocker: Have You Seen Elon Musk’s Miracle? (From InvestorPlace) (Ad) Free LPCN Stock Alerts $6.04 +0.29 (+5.04%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$5.74▼$6.3050-Day Range$3.61▼$6.5152-Week Range$2.31▼$7.15Volume49,113 shsAverage Volume30,679 shsMarket Capitalization$32.31 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Lipocine alerts: Email Address Ad Crypto 101 MediaThe Overlooked Retirement Asset You Probably Don’t Own4 out of 5 Americans believe we’re on the brink of a retirement crisis. Luckily, in these unprecedented times, we have an unprecedented solution. Once considered a “fringe” investment, the crypto market is now taking the world by storm.Click here to access the Crypto Retirement Blueprint now. About Lipocine Stock (NASDAQ:LPCN)Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.Read More LPCN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LPCN Stock News HeadlinesMay 13, 2024 | americanbankingnews.comLipocine (NASDAQ:LPCN) Research Coverage Started at StockNews.comMay 9, 2024 | investorplace.comLPCN Stock Earnings: Lipocine Beats EPS for Q1 2024May 9, 2024 | finance.yahoo.comLipocine Announces Financial Results for the First Quarter Ended March 31, 2024May 8, 2024 | prnewswire.comLipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024May 1, 2024 | prnewswire.comLipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154April 12, 2024 | msn.comLipocine hopes obesity drug could boost muscle mass in combo with GLP1-RAsApril 11, 2024 | finanznachrichten.deLipocine Inc.: Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with ObesityApril 11, 2024 | fr.investing.comLipocine annonce les résultats positifs d'une étude sur le traitement de l'obésitéApril 11, 2024 | markets.businessinsider.comLipocine Reports Positive Phase 2 Results For LPCN 2401 In Participants With ObesityApril 11, 2024 | finance.yahoo.comLipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with ObesityApril 11, 2024 | prnewswire.comLipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with ObesityMarch 28, 2024 | finanznachrichten.deLipocine Inc.: Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with CirrhosisMarch 28, 2024 | markets.businessinsider.comLipocine: LPCN 1148 Meets Primary And Hepatic Encephalopathy Endpoints In Phase 2 StudyMarch 28, 2024 | prnewswire.comLipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with CirrhosisMarch 25, 2024 | finance.yahoo.comCirrhosis Clinical Trial Pipeline Insights Featuring 45+ Companies | DelveInsightMarch 25, 2024 | prnewswire.comLipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154March 7, 2024 | investorplace.comLPCN Stock Earnings: Lipocine Beats EPS for Q4 2023March 7, 2024 | seekingalpha.comLipocine GAAP EPS of -$3.14March 7, 2024 | prnewswire.comLipocine Announces Financial Results for the Full Year Ended December 31, 2023March 6, 2024 | finance.yahoo.comLipocine to Present at 36th Annual Roth ConferenceFebruary 6, 2024 | finance.yahoo.comLipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154February 2, 2024 | finanznachrichten.deLipocine Inc.: Lipocine Announces Continued Commercialization of TLANDO through Verity PharmaceuticalsFebruary 2, 2024 | fr.investing.comLipocine transfère la commercialisation de TLANDO à Verity PharmaFebruary 2, 2024 | finance.yahoo.comLipocine Announces Continued Commercialization of TLANDO® through Verity PharmaceuticalsJanuary 18, 2024 | marketwatch.comLipocine Shares Rise Premarket on Tlando Licensing DealSee More Headlines Receive LPCN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lipocine and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today5/18/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:LPCN CUSIPN/A CIK1535955 Webwww.lipocine.com Phone(801) 994-7383Fax801-994-7388Employees17Year Founded1997Profitability EPS (Most Recent Fiscal Year)($1.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-16,350,000.00 Net MarginsN/A Pretax Margin-190.34% Return on Equity-37.62% Return on Assets-34.60% Debt Debt-to-Equity RatioN/A Current Ratio16.99 Quick Ratio16.99 Sales & Book Value Annual Sales$4.71 million Price / Sales6.86 Cash FlowN/A Price / Cash FlowN/A Book Value$4.48 per share Price / Book1.35Miscellaneous Outstanding Shares5,348,000Free Float5,021,000Market Cap$32.30 million OptionableNo Data Beta1.11 Social Links These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesDr. Mahesh V. Patel Ph.D. (Age 67)Co-Founder, Interim Principal Financial Officer, Director, President & CEO Comp: $598.91kMs. Krista Fogarty (Age 56)Principal Accounting Officer & Corporate Controller Comp: $268.12kDr. Nachiappan Chidambaram Ph.D. (Age 54)Senior Vice President of Research & Development Comp: $311.17kMr. Logan Morse (Age 54)Vice President of Sales, Marketing & Operations Comp: $413.58kMr. Morgan R. Brown CPA (Age 56)M.B.A., Corporate Secretary Comp: $472.45kKey CompetitorsDURECTNASDAQ:DRRXTheratechnologiesNASDAQ:THTXEnlivex TherapeuticsNASDAQ:ENLVNanoViricidesNYSE:NNVCJanOneNASDAQ:JANView All CompetitorsInsidersMahesh V PatelBought 8,706 shares on 5/25/2023Total: $43,791.18 ($5.03/share)View All Insider Transactions LPCN Stock Analysis - Frequently Asked Questions How have LPCN shares performed in 2024? Lipocine's stock was trading at $2.79 on January 1st, 2024. Since then, LPCN stock has increased by 116.5% and is now trading at $6.04. View the best growth stocks for 2024 here. When is Lipocine's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our LPCN earnings forecast. How were Lipocine's earnings last quarter? Lipocine Inc. (NASDAQ:LPCN) announced its earnings results on Thursday, May, 9th. The specialty pharmaceutical company reported $0.66 EPS for the quarter. The specialty pharmaceutical company had revenue of $7.62 million for the quarter. When did Lipocine's stock split? Lipocine shares reverse split before market open on Friday, May 12th 2023. The 1-17 reverse split was announced on Friday, May 12th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. What other stocks do shareholders of Lipocine own? Based on aggregate information from My MarketBeat watchlists, some companies that other Lipocine investors own include Synergy Pharmaceuticals (SGYP), Flexion Therapeutics (FLXN), Trevena (TRVN), Heat Biologics (HTBX), Rigel Pharmaceuticals (RIGL), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Biocept (BIOC) and Catalyst Pharmaceuticals (CPRX). How do I buy shares of Lipocine? Shares of LPCN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LPCN) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersBuy this small stock before coming AI Tidal WaveChaikin AnalyticsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingShocking $16T Elon Musk Crypto LeakCrypto 101 MediaForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsDems have chosen Biden replacement?Paradigm PressHow Biden has already won 2024Porter & CompanyExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersA letter is coming from the "Bureau of the Fiscal Service".Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lipocine Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.